Yuan Da Xin Xi·2026-01-19 12:05Group 1: Drivers of Excess Returns from Stock Buybacks - Stock buybacks are positively correlated with the buyback ratio, where higher buyback ratios lead to greater excess returns. The highest excess returns for companies with buyback ratios over 5% are 4.48% and 4.36% for the 5th and 4th groups, respectively, while other groups yield less than 1.5% [1][11] - The valuation logic of "stronger gets stronger" and "undervaluation recovery" exists post-buyback announcement. Companies with low valuation (1st group) show a significant excess return of 7.45%, while the highest and lowest valuation groups yield 3.32% and 2.11% excess returns, respectively, over 90 days post-announcement [1][13] Group 2: Recent Stock Buyback Activities - From January 12 to January 16, 2026, 16 companies with more than 10 institutional ratings announced buybacks, with Salted Fish (盐津铺子) being notable for a buyback ratio exceeding 1%. Proya (珀莱雅) is recommended for its low PE percentile over the past three years [2][17] - Salted Fish efficiently completed its buyback, demonstrating strong confidence in its value, with revenue of 4.427 billion and net profit of 605 million in the first three quarters of 2025. The company is upgrading its distribution channels and enhancing profitability [2][19] - Proya initiated its first buyback on January 15, 2026, repurchasing 230,800 shares with a total plan amounting to 80 million to 150 million. The company reported revenue of 7.098 billion and net profit of 1.026 billion in the first three quarters of 2025, with a gross margin of 73.69% [2][19] Group 3: Yearly Stock Buyback Overview - From January 16, 2025, to January 16, 2026, 28 companies with more than 10 institutional ratings announced buybacks, with notable mentions being Jian Sheng Group (健盛集团) and Jingxin Pharmaceutical (京新药业) for buyback ratios exceeding 5% [3][20] - Jian Sheng Group initiated a buyback plan in October 2025, using 150 million to 300 million in self-funds and loans, with a maximum buyback price of 14.69 per share. The company reported revenue of 1.886 billion and net profit of 309 million in the first three quarters of 2025, with a significant cash flow increase of 72.95% [3][23] - Jingxin Pharmaceutical started its buyback plan in January 2025, planning to use 350 million to 700 million in self-funds for employee stock ownership plans. The company reported revenue of 3.048 billion, a slight decline of 5.0%, and a net profit of 576 million, with a non-recurring net profit growth of 8.92% [3][23]